Related articles

In recent years, the incidence of cancer among younger populations has been increasing at an alarming rate. More individuals in their 20s, 30s, and 40s are being diagnosed with various forms of cancer. Factors such as lifestyle changes, environmental pollution, chronic stress, and genetic predisposition are contributing to this trend. However, conventional cancer screening methods are primarily designed for older adults, leaving younger individuals without regular early detection opportunities. As a result, cancers in younger patients are often diagnosed at later stages, reducing the chances of successful intervention. RGCC personalized cancer testing offers a groundbreaking solution by detecting circulating tumor cells (CTCs) and cancer stem cells (CSCs) in the blood, allowing for early detection and providing personalized care strategies. This advanced technology is particularly valuable for younger populations, enabling proactive cancer prevention, early intervention, and tailored management plans.

In the care process of cancer patients, there is often a gap period between initial treatments (such as surgery, chemotherapy, or radiotherapy) and regular follow-up visits. During this time, patients may not exhibit obvious symptoms, but residual or newly-formed tumor cells may persist, posing a risk of recurrence or metastasis. Traditional imaging techniques (such as CT or MRI) have limited sensitivity in detecting small lesions. Therefore, dynamic monitoring of micro-residual cancer cells during these gaps is crucial.

Hong Kong has one of the highest liver cancer incidence rates globally, largely due to chronic hepatitis B virus (HBV) infection, alcohol consumption, and fatty liver disease. However, early-stage liver cancer often presents no obvious symptoms, leading to late diagnoses when treatment options become more limited. This makes a highly sensitive and convenient early detection method crucial.

Lung cancer remains one of the most challenging malignancies worldwide due to its high mortality rate and often late-stage diagnosis. Early detection and personalized care strategies are critical in improving patient outcomes. RGCC’s Circulating Tumor Cell (CTC) testing offers a promising approach for monitoring lung cancer progression, treatment response, and recurrence risk. This article explores the latest clinical applications of RGCC CTC testing in lung cancer care.

When doctors diagnose cancer, they classify it into different stages to determine the tumor’s size, spread, and severity. Cancer staging not only helps in deciding the best treatment plan but also in predicting survival rates. Below is a detailed explanation of cancer stages from Stage 0 to Stage 4 in a simple and easy-to-understand way.